Université De Nantes

Ose Immunotherapeutics

Institut National De La Sante Et De La Recherche Medicale

Inserm (institut National De La Sante Et De La Recherche Medicale)

Nantes Université

Inserm

Elise Chiffoleau

Nicolas Poirier

Vanessa Gauttier

Bernard Vanhove

Géraldine Teppaz

Geraldine Teppaz

Caroline Mary

Sabrina Pengam

Marion Drouin

The invention pertains to the field of immunotherapy. The present invention provides specific humanized anti-CLEC-1A antibodies, antigen-binding fragments thereof and mimetics thereof, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The compounds of the invention can be used to treat deleterious conditions.

Humanized anti-CLEC-1A antibodies and antigen-binding fragments thereof

The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.

Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)

Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)

Growing community of inventors

Nantes, France

Elise Chiffoleau